Head-to-head · WeighScore
CoreAge Rx vs SkinnyRx
By GLP-1 ScorecardUpdated
Score comparison
CoreAge Rx has the higher recorded score — 89.5/100 to 60.5/100.
CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
CoreAge Rx scores 89.5/100 (B+).
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | CoreAge Rx | SkinnyRx |
|---|---|---|
| WeighScore | 89.5/100 | 60.5/100 |
| Grade | B+ | C |
| Site position | #1 | #284 |
| Semaglutide | Product page from $79/mo; navigation $99. Confirm selected quote. | Injection advertised $99 first month; compounded tablets $149 first month. Confirm the recurring price, selected term and usable prescription supply. |
| Tirzepatide | From $129/mo advertised; confirm selected charge, supply and renewal. | Injection advertised $99 first month; compounded dissolving tablets $199 first month. Confirm the recurring price, selected term and usable prescription supply. |
| Coverage | US only; therapy-specific state restrictions apply | Current terms exclude certain compounded offerings in Alabama, Louisiana and Mississippi; confirm eligibility for the exact route and pharmacy. |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Yes |
Site position #1 · B+
Strengths
- Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
- Advertises the same price across doses and no membership fee
- Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy
What to consider
- Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
- FAQ no-rebill and payment-timing statements differ from the subscription and order policy
- FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
- Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
- Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation
Site position #284 · C
FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.
Strengths
- Advertises separate first-month prices for both compounded molecules and both injection and tablet routes
- Current terms describe the ninety-day commercial guarantee’s dose logging, claim-window, promotional eligibility and coverage requirements
- Names a medical director/advisor in public information; this does not identify the assigned treating professional
- Publishes compounded-treatment state exclusions and cancellation channels rather than leaving every operational detail unspecified
What to consider
- First-month prices do not establish the recurring amount, selected full prepayment or usable medication quantity
- Cancellation requires five days’ notice before renewal processing, which can itself precede the next subscription period
- The guarantee’s bundled-refund language needs clarification alongside general third-party-fee deductions, medication-return requirements and product FAQ restrictions
- Microdose badges and daily tablet descriptions do not establish a separate price, complete prescription or equivalent branded-treatment results
- The actual prescribing practice, assigned clinician, dispensing pharmacy, physical compounder and patient-lab costs remain unconfirmed
- The named advisor’s Florida record flags discipline and a public complaint, while Oregon lists a surrendered license; neither record determines every clinician’s authority or the patient assignment
- FDA issued Lean Rx Inc. dba SkinnyRx a warning letter on February 20, 2026; website testing claims do not establish independent pharmacy verification.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.